CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...